ADIL · Adial Pharmaceuticals, Inc.
$3.29
+0.14 (+4.44%)
At close · Jul 30
Going-concern doubt
— flagged May 8, 2026
Substantial doubt about the company's ability to continue as a going concern.
“the Company does not believe that the existing cash and cash equivalents are sufficient to fund operations for the next twelve months following the filing of these unaudited condensed financial statements. During 2026, the Company received net proceeds of approximately $0.3 million from equity issuances. However, the Company will require additional capital to continue operations and development of AD04. These factors raise substantial doubt about the Company’s ability to continue as a going concern.”View the 10-Q filed May 8, 2026
Market Cap
$7.05M
Shares
2.14M
Share-repurchase activity from the company's own XBRL filings — cash spent buying back common stock per fiscal year and per recent quarter, share counts where the company tagged them, and the buyback program's authorization — paired with the company's at-the-market (ATM) equity offering programs, the dilution side of the same picture. Repurchase amounts come exclusively from tagged SEC data; program figures with no tagged equivalent (untagged authorizations and all ATM figures) are read from the filing's own text and shown only after verification.
Program Authorized
26,665 shares
as of 2023-12-31
· not restated in filings since 2024-04-01
Remaining Authorization
13,335 shares
as of 2023-12-31
· not restated in filings since 2024-04-01
Program Utilization
50.0%
13,330 shares used of 26,665 shares
Equity Offering (ATM) Programs
| Program Established | Capacity | Remaining | As of | Runs Through | Source |
|---|---|---|---|---|---|
| 2025-08-01 | $4,983,000 | — | — | — | 10-Q , filed 2025-11-13 |
Repurchase History
| Fiscal Year Ended | Cash Spent | Source |
|---|---|---|
| 2023-12-31 | $1,661 | 10-K, filed 2025-03-04 |
Key facts
CIK
1513525
CUSIP
00688A304
13F (30d)
30 filings
5 filers
Visit website
Investor relations